[Skip to Navigation]
Sign In
Correction
March 2018

Errors in Abstract and Figures 2 and 3

JAMA Neurol. 2018;75(3):384. doi:10.1001/jamaneurol.2017.4512

In the Original Investigation titled “Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial,”1 published in the November 2017 issue, there were errors in the Abstract and Figures 2 and 3. In the Objective section of the Abstract, the sentence “To assess whether older, Asian, or severely affected patients with AIS who are considered at high risk of thrombolysis may benefit more from low-dose rather than standard-dose alteplase treatment” should have read “at high risk of bleeding after thrombolysis.” In Figure 2, under the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST), the odds ratio for an age of 70 to 79 years should be 0.70. In Figure 3, the percentage of Asian patients who received low-dose alteplase and had a modified Rankin Scale (mRS) score of 1 should be 21.7%; the percentages of non-Asian patients who received low-dose alteplase and had mRS scores of 0, 1, and 2 should be 22.0%, 21.6%, and 17.0%, respectively; and the percentages of non-Asian patients who received standard-dose alteplase and had mRS scores of 0, 1, and 2 should be 19.9%, 25.4%, and 15.4%, respectively. This article was corrected online.

References
1.
Wang  X, Robinson  TG, Lee  TH,  et al; Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) Investigators.  Low-dose vs standard-dose alteplase for patients with acute ischemic stroke: secondary analysis of the ENCHANTED randomized clinical trial.  JAMA Neurol. 2017;74(11):1328-1335. PubMedGoogle ScholarCrossref
×